Recruiting
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
About this study
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.
- Condition
- Breast Carcinoma
- Tested
- Laboratory Biomarker Analysis
- Sponsor
- National Cancer Institute (NCI)
Who can join
- Age
- Not specified
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Study condition: Breast Carcinoma
- European American patients with DNA available
- European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab
- African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls
Where
1 site, 1 recruiting
Eastern Cooperative Oncology Group
Boston, Massachusetts, United States
Potential match only. Final eligibility is determined by the study team.